According to the Zhitong Finance App, Yeju Medical (06929.HK) announced that the key clinical trial (OM-0031) conducted in Japan has completed the first patient enrollment. This trial will evaluate coronary paclitaxel drug-coated balloons (“drug-coated balloons”, DCB) independently developed by the Group, marking an important step in consolidating the Group's leading position in the Japanese interventional cardiology market with a diversified product portfolio.

According to the Zhitong Finance App, Yeju Medical (06929.HK) announced that the key clinical trial (OM-0031) conducted in Japan has completed the first patient enrollment. This trial will evaluate coronary paclitaxel drug-coated balloons (“drug-coated balloons”, DCB) independently developed by the Group, marking an important step in consolidating the Group's leading position in the Japanese interventional cardiology market with a diversified product portfolio.